Additionally, while outside the scope of this review focusing on immunotherapies for high-grade gliomas, a recent pilot study evaluating the safety and immunogenicity of IMA950/poly-ICLC combined with the agonistic anti-CD27 antibody varlilumab in low-grade gliomas is worth noting. Here, CD27 is linked to glioma.